Skip to content

Improving Tissue Oxygenation in Breast Reconstruction Surgery

Perioperative Tissue Oxygenation

Breast reconstruction is an integral part of breast cancer care. There are two main types of breast reconstruction: alloplastic (using implants), and autologous (using patient's tissue). The latter creates a more natural breast mound, and avoids long-term concerns requiring surgical re-intervention associated with implant-based surgery. The deep inferior epigastric perforator (DIEP) flap is the gold standard technique in autologous breast reconstruction. Complications, however, do occur with DIEP flap surgery and often stem from poor flap perfusion/oxygenation. Hence, the development of strategies to enhance flap perfusion (e.g., optimal perioperative fluid therapy) is essential. Current perioperative fluid therapy is usually guided by subjective criteria which leads to wide variations in fluids administered. We will randomly assign DIEP flap patients to receive optimal (cardiac output-guided) fluid therapy in combination with dobutamine (a medication which has potential to improve flap oxygenation) versus the current standard of care. Flap oxygenation will be monitored via near-infrared spectroscopy in all patients for up to 48 hours postoperatively. Optimal fluid therapy in combination with dobutamine may improve flap oxygenation and thereby, reduce complications.

null

Conditions de participation

  • Sexe:

    FEMALE
  • Âges admissibles:

    18 to 80

Critères de participation

Inclusion Criteria:

* American Society of Anesthesiologists' (ASA) Physical Classification I-III;
* Undergoing elective unilateral or bilateral DIEP flap surgery;
* Competent to provide informed consent.

Exclusion Criteria:

* Dementia or neurological impairment;
* Scheduled for DIEP flap combined with any other secondary surgical procedure;
* Documented left ventricular dysfunction (ejection fraction \< 40%);
* Contraindication to low-dose dobutamine;
* Body mass index \< 18 or \> 40 kg/m2;
* Pregnant or lactating;
* Renal insufficiency (eGFR \< 30 ml/min/1.73m2);
* Known liver insufficiency (i.e., documented cirrhosis, coagulopathy and/or encephalopathy of hepatic origin).

Lieu de l'étude

Kingston General Hospital
Kingston General Hospital
Kingston, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Debbie DuMerton, RN

[email protected]
(613) 548-7827
Hotel Dieu Hospital
Hotel Dieu Hospital
Kingston, Ontario
Canada

Contactez l'équipe d'étude

Backup Contact

Glenio B. Mizubuti, MD, MSc, FRCPC

[email protected]
(613) 548-7827
Primary Contact

Debbie DuMerton, RN

[email protected]
(613) 549-6666
Étude parrainée par
Queen's University
Participants recherchés
Plus d'informations
ID de l'étude: NCT04020172